Overview
- The findings were presented at the American Headache Society annual meeting, held June 4–7 in Orlando, and draw on thousands of daily headache entries from HALO‑EM and HALO‑LTS Phase 3 trial sites in the Northeastern U.S.
- Investigators matched those diaries to four years of National Climatic Data Center records organized into three‑day windows and identified two high‑risk weather systems: an approaching cold front with precipitation and the Bermuda High high‑pressure system.
- Trial data showed that treatment with the preventive monoclonal antibody fremanezumab (Ajovy) cut new‑onset headache rates across all weather patterns and appeared to erase the weather–headache link as early as one month and after six months of use.
- The study used a multi‑variable, pattern‑based meteorological analysis rather than single weather variables and found the weather–headache relationship varied by region and season within the study area.
- Teva Pharmaceuticals funded and collaborated on the research, and authors say independent replication and clearer biological explanations are needed before the results guide wider clinical practice.